National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 1 of 1 Research Studies DisplayedYun H, Xie F, Delzell E
Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare.
The aim of this study was to determine whether the associated risk of hospitalized infections differed between specific biologic agents used to treat rheumatoid arthritis (RA). It concluded that RA patients with prior exposure to a biologic agent, exposure to etanercept, infliximab, or rituximab was associated with a greater 1-year risk of hospitalized infection compared with the risk associated with exposure to abatacept.
AHRQ-funded; HS021694; HS018517.
Citation: Yun H, Xie F, Delzell E .
Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare.
Arthritis Rheumatol 2016 Jan;68(1):56-66. doi: 10.1002/art.39399..
Keywords: Comparative Effectiveness, Healthcare-Associated Infections (HAIs), Arthritis, Hospitalization, Risk